AQST Aquestive Therapeutics Inc

Price (delayed)

$2.65

Market cap

$176.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.2

Enterprise value

$261.55M

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, ...

Highlights
The EPS has surged by 88% year-on-year and by 50% since the previous quarter
AQST's net income has surged by 83% year-on-year and by 46% since the previous quarter
The company's gross profit fell by 13% YoY but it rose by 5% QoQ
Aquestive Therapeutics's gross margin has decreased by 13% YoY but it has increased by 2.2% QoQ

Key stats

What are the main financial stats of AQST
Market
Shares outstanding
66.77M
Market cap
$176.93M
Enterprise value
$261.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.44
Earnings
Revenue
$48.06M
EBIT
-$6.04M
EBITDA
-$4.76M
Free cash flow
$6M
Per share
EPS
-$0.2
Free cash flow per share
$0.09
Book value per share
-$1.67
Revenue per share
$0.74
TBVPS
$0.9
Balance sheet
Total assets
$59.45M
Total liabilities
$162.38M
Debt
$109.53M
Equity
-$102.93M
Working capital
$18.4M
Liquidity
Debt to equity
-1.06
Current ratio
1.76
Quick ratio
1.39
Net debt/EBITDA
-17.77
Margins
EBITDA margin
-9.9%
Gross margin
55.4%
Net margin
-25.2%
Operating margin
-45.6%
Efficiency
Return on assets
-20.6%
Return on equity
N/A
Return on invested capital
-5.5%
Return on capital employed
-17.1%
Return on sales
-12.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
-1.67%
1 week
0%
1 month
8.61%
1 year
225.59%
YTD
31.19%
QTD
31.19%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$48.06M
Gross profit
$26.6M
Operating income
-$21.9M
Net income
-$12.11M
Gross margin
55.4%
Net margin
-25.2%
The net margin has soared by 83% YoY and by 48% from the previous quarter
AQST's net income has surged by 83% year-on-year and by 46% since the previous quarter
Aquestive Therapeutics's operating margin has increased by 49% YoY and by 25% QoQ
The operating income has increased by 49% YoY and by 23% from the previous quarter

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.44
The EPS has surged by 88% year-on-year and by 50% since the previous quarter
AQST's equity is up by 4.5% year-on-year and by 3.5% since the previous quarter
AQST's P/S is 123% above its last 4 quarters average of 1.6 and 49% above its 5-year quarterly average of 2.4
Aquestive Therapeutics's revenue has increased by 3.3% from the previous quarter

Efficiency

How efficient is Aquestive Therapeutics business performance
The return on sales has surged by 89% year-on-year and by 58% since the previous quarter
The company's return on invested capital has surged by 88% YoY and by 57% QoQ
AQST's ROA has soared by 84% year-on-year and by 48% since the previous quarter

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 63% lower than its total liabilities
Aquestive Therapeutics's quick ratio has surged by 74% YoY and by 65% QoQ
The current ratio has surged by 71% since the previous quarter and by 69% year-on-year
The debt has contracted by 9% YoY
AQST's debt to equity is up by 5% year-on-year but it is down by 2.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.